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Background. Bariatric surgery patients have a higher prevalence of nonalcoholic fatty liver (NAFL) than the general population;
however, its assessment and the accurate staging of fibrosis are often complicated because noninvasive tests are not very
accurate in patients with morbid obesity, and liver biopsy cannot be performed as a routine exam. The aim of this study was to
evaluate (A) the histological prevalence of NAFL, nonalcoholic steatohepatitis (NASH), and fibrosis in patients undergoing
bariatric surgery; (B) the reliability of ultrasound (US) in diagnosing NAFL; and (C) the reliability of various fibrosis scoring
systems for defining fibrosis. Methods. US and intraoperative liver biopsy results were reviewed in 57 bariatric surgery patients.
NAFL, NASH, and fibrosis were diagnosed according to the Kleiner scoring system. US diagnosis of liver steatosis was based on
the bright liver. Fibrosis scores used were (i) the BMI, AST/ALT Ratio, Diabetes (BARD) scoring system; (ii) the nonalcoholic
fatty liver disease (NAFLD) fibrosis score; and (iii) the fibrosis-4 (FIB-4) index. Results. The prevalence of NAFL was 81%,
NASH 61.4%, and fibrosis 94% (F3 5.7%, cirrhosis 2.8%). The sensitivity of US was 95%, specificity 50%, and likelihood ratio
(LR+, LR-) 1.91 and 0.1. The reliability of fibrosis scores for F ≥ 2 were as follows: BARD score: sensitivity 46%, specificity 54%,
and area under the receiver-operating characteristics (AUROC) curve 0.5; NAFLD score: sensitivity 30%, specificity 89%, and
AUROC 0.5; and FIB-4: sensitivity 68%, specificity 67%, and AUROC 0.7. Conclusions. In bariatric surgery patients, the
prevalence of NAFL was 81%, NASH 61.4%, and fibrosis 94%. US is able to rule out the presence of NAFL, while the commonly
used scores may be inaccurate in defining fibrosis in patients with morbid obesity.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is a very common
chronic liver disease worldwide, and in Western countries,
it is the most frequent type of liver disease [1–7]. Diagnosis
is based on an abnormal accumulation of fat in more than
5% of hepatocytes at liver biopsy, in the absence of other
causes such as alcohol abuse, viral infection, autoimmune,
or drug-related liver diseases. Since being overweight, obesity
(especially visceral), dyslipidemia, and diabetes mellitus are
recognized as risk factors for NAFLD, it is considered a com-
ponent of metabolic syndrome (MS) [7–9].
The term NAFLD covers a wide spectrum of diseases,
ranging from simple steatosis (NAFL) to nonalcoholic
steatohepatitis (NASH), in which steatosis is associated
with ballooning degeneration of hepatocytes and diffuse
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lobular inflammation; this is the form that can evolve
towards liver fibrosis of varying degrees of severity, up to
cirrhosis and hepatocellular carcinoma (HCC) [1–6].
Morbid obesity is often defined as a body mass index
(BMI) exceeding 35 kg/m2 combined with at least one
obesity-associated disease, or a BMI exceeding 40 kg/m2 with
or without obesity-associated diseases [10]. NAFLD occurs
frequently in people with morbid obesity, and it has been
reported in 80-90% of patients undergoing bariatric surgery.
An estimated 20-47% of these patients have NASH, of which
8-12% progress to cirrhosis and an undefined percentage to
HCC [8–10]. From these data, it is clear that NAFLD, in its
various stages of evolution, can adversely affect the health
and survival of these patients. Therefore, the accurate evalu-
ation of the presence of steatosis and the correct staging of
fibrosis are important for the accurate assessment of these
subjects’ prognoses.
The gold standard for diagnosing steatosis and fibrosis
is liver biopsy, but this is not always feasible as, in most
patients, liver disease is asymptomatic and often without
laboratory indications [1]. Several noninvasive tests have
been proposed for defining fibrosis [1], and for the diag-
nosis of fatty liver disease, ultrasound (US) is certainly a
reliable method, well accepted by patients and sufficiently
accurate [10–14]. However, for fibrosis, elastography, con-
sidered the most reliable method for diagnosing chronic
liver disease, is not sufficiently accurate in people with
morbid obesity. Consequently, a number of alternative
scores have been proposed [1, 15]. The most commonly
used of these are the BMI, AST/ALT Ratio, Diabetes
(BARD) scoring system, the NAFLD fibrosis score, and
the fibrosis-4 (FIB-4) index [1, 16–18].
The aim of our study was to retrospectively evaluate (A)
the histological prevalence of liver steatosis and fibrosis in a
population of patients undergoing bariatric surgery; (B) the
reliability of US in the diagnosis of steatosis; (C) the reli-
ability of the various fibrosis scores listed above for defining
liver fibrosis.
2. Patients and Methods
2.1. Patient Selection. We retrospectively examined US liver
images and the results of intraoperative liver biopsies in 57
patients undergoing bariatric surgery, consecutively enrolled
between January 2015 and December 2018 at the Bariatric
Surgery Unit of the University Hospital of Palermo, Italy.
The study was conducted in accordance with the ethical
standards laid down in the Helsinki Declaration of 1975
and its subsequent amendments and was approved by
the Ethics Committee as a spontaneous study on 23 June
2014 (No. 7/2014). All patients gave their approval and
signed informed consent.
Before surgery, all patients had been interviewed and
examined during an outpatient visit. A standard question-
naire was used to investigate the presence of metabolic, car-
diovascular, or liver diseases, use of any hepatotoxic drugs,
and alcohol consumption.
The patients then underwent a physical examination in
which weight (kg), height (m), and BMI were measured.
Blood pressure was evaluated with the patient in a sitting
position, and hypertension was diagnosed according to the
WHO/ISH criteria [19]. A blood sample was also taken from
patients the morning before surgery to measure levels of glu-
cose, total cholesterol and HDL, triglycerides, aminotransfer-
ases (AST/ALT), and insulin.
Diagnosis of type-2 diabetes mellitus (T2DM), impaired
fasting glycemia (IFG), and impaired glucose tolerance
(IGT) was performed in accordance with the expert commit-
tee on criteria for the diagnosis and classification of diabetes
mellitus [20]. Insulin resistance was calculated using total
insulin and glucose levels, following the homeostasis model
assessment (HOMA-R) [21]. Patients with elevated transam-
inase values were tested for anti-HCV, HBsAg, ANA, AMA,
ASMA, and LKM1 antibodies.
US was performed by a single operator the morning
before surgery, after 10 hours of fasting, using a Philips
5000 HDI US machine with a 2-5MHz convex multifre-
quency probe. NAFLD diagnosis was based on the presence
of the bright liver on US [7]. Patients were divided into
NAFLD-US positives or negatives.
Serum fibrosis scores were obtained using the following
methods:
(1) BARD scoring system, which consists of three vari-
ables: BMI > 28, 1 point; AST/ALT ratio > 0:8, 2
points; and T2DM, 1 point. The score varies from 0
to 4 points. According to Harrison et al. [17], scores
of 2-4 points are associated with F3 or F4 stages of
fibrosis, with an odds ratio of 17.333 (95% Cl;
3.639–82.558) and a negative predictive value of 97%
(2) NAFLD fibrosis score, established with the follow-
ing formula: −1:675 + 0:037 − age ðyearsÞ + 0:094 −
BMI ðkg/m2Þ + 1:13 × IFG/diabetes ðyes = 1, no = 0Þ +
0:99 × AST/ALT ratio − 0:013 × platelet count ð× 109/LÞ
− 0:66 × albumin ðg/dLÞ. According to Angulo et al.
[18], a score below -1.455 (low cut-off) excludes
advanced fibrosis, while a score higher than 0.676
predicts advanced fibrosis. The scores between
these values are defined as indeterminate
(3) FIB-4 index: age × AST ðU/LÞ/plateletsð109/L/
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ALTðU/LÞp [16].
2.2. Liver Histology.Wedge or core liver biopsies to the depth
of Glisson’s capsule were obtained shortly after the abdomi-
nal cavity was opened and before manipulation of the liver.
Liver biopsies were routinely formalin-fixed and paraffin-
embedded. Hematoxylin and eosin (H&E) and picrosirius
staining were available for each case. Slides were read by
one expert pathologist (D.C.) who was unaware of patient
identities and histories. A minimum biopsy specimen length
of 15mm or the presence of at least 10 complete portal tracts
was required.
The Kleiner scoring system was used as a protocol for the
histological assessment of steatosis [22]. This system evalu-
ates the degree of NAFLD by assigning separate scores for
steatosis, hepatocellular ballooning, lobular inflammation,
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and stage of fibrosis. Fibrosis was assessed on the 5-point
scale (0-4) suggested by Kleiner et al. [22], in which stages
F0= absence of fibrosis, F1=perisinusoidal or periportal
fibrosis, F2=perisinusoidal and portal/periportal fibrosis,
F3=bridged fibrosis, and F4= cirrhosis.
The presence of NASH was assessed using the steatosis,
activity, and fibrosis (SAF) score [23].
All patients who had an etiologically well-defined liver
disease were excluded from the study.
2.3. Statistical Analysis. Data were expressed as mean ±
standard deviation (SD) or as median and range (min-max).
The prevalence of steatosis and fibrosis, sensitivity (Se),
specificity (Sp), positive predictive value (PPV), negative
predictive value (NPV), accuracy (Acc), and positive and
negative likelihood ratio (LR+, LR-) were calculated using
classical formulas. The receiver-operating characteristic
(ROC) curve was constructed by calculating the sensitivity
and specificity of individual serum fibrosis tests at different
cut-off points, and the corresponding area under the curve
(AUROC) was calculated to evaluate the diagnostic accuracy
of the tests in differentiating F ≥ 2 [24]. The best cut-off value
was calculated as the maximum LR obtained using the follow-
ing formula: LR = probability of true positive + probability of
true negative/probability of false positive + probability of false
negative [25].
3. Results
Table 1 shows the clinical and demographic characteristics of
the enrolled patients. Liver steatosis, defined as the accu-
mulation of fatty acid in more than 5% of hepatocytes,
was present in 46/57 biopsies (Figure 1(a)), with a preva-
lence of 81% (95% CI: 71-90). Figure 1(a) shows the stea-
tosis grading according to the Kleiner scoring system. In
particular, <5% (nonsteatosis, Grade 0) was found in
17.9% of biopsies; 5-33% (Grade I) in 30.4%; 33%-66%
(Grade II) in 26.8%; and >66% (Grade III) in 25%.
Table 2 shows the diagnostic reliability data of US for
steatosis diagnosis. Sensitivity was 95% (95% CI: 81-98),
specificity 50% (95% CI: 18-75), PPV 89.4 (95% CI: 82-94),
NPV 71% (95% CI: 36-92), accuracy 87% (95% CI: 75-94),
positive LR 1.91 (95% CI: 1.1-3.5), and negative LR 0.1
(95% CI: 0.02-0.4).
Figure 1(b) shows the prevalence of NASH. NASH was
present in 35/57 patients (61.4%; 95% CI: 58-73%). Of the
46 patients with steatosis, fibrosis was present in 40 (87%;
95% CI: 75-95). In patients with NASH, fibrosis was present
in 33/35 (94%; 95% CI: 0.89-0.98) (Figure 1(c)), divided as
follows: F0 fibrosis in 2 cases (5.7%; 95% CI: 1-30%), F1 in
12 cases (34.1%; 95% CI: 21-50%), F2 in 18 patients (51%;
95% CI: 18-35%), F3 (bridging fibrosis) in 2 patients (5.7%;
95% CI: 1-30%), and F4 (cirrhosis) in 1 case (2.8%; 95%
CI: 0.5-20).
The AUROC curves of the individual fibrosis tests and
the best diagnostic cut-off values were calculated. The reli-
ability of serum fibrosis scores in defining F ≥ 2 at the best
cut-off values is shown in Table 3. Figure 2 shows the
AUROC curve of the FIB-4 index with an AUROC of 0.7
and the best cut-off point.
4. Discussion
Liver steatosis is considered the most frequent liver disease,
especially inWestern countries, and its prevalence is growing
worldwide: 44% in the USA, 33% in Europe, and 25% in Italy.
NAFLD is associated with obesity, dyslipidemia, and diabetes
mellitus, and its prevalence varies according to the popula-
tions observed and the diagnostic methods used, including
histology, US, elastography, or magnetic resonance imaging
[1–7]. In patients with MS and dyslipidemia, a 78% preva-
lence of liver steatosis detected by US has been reported. In
diabetics, the prevalence was between 30% and 80%, while
in obese patients, it increased to between 81% and 87% [1–7].
NAFLD is associated with a higher mortality rate for car-
diovascular, liver, and cancer diseases than the general popu-
lation. In liver disease, the correct evaluation of a patient’s
histological evolution is crucial in defining prognosis [3].
The presence of fibrosis and its evolution towards cirrhosis
negatively impact the survival of NAFLD patients.
The prevalence of steatosis in liver biopsies in our
series was 81%, similar to the data reported in the litera-
ture. In contrast, the reliability of US in diagnosing steato-
sis in our study differed from values defined for the
general population, where sensitivity has been estimated
at 74%-91% and specificity at 85%-98%, depending on
the case series considered [10–14]. In our study, sensitivity
was comparable to data reported for the general popula-
tion, whereas our 50% specificity was unsatisfactory. Liter-
ature data in the past have reported conflicting results for
specificity in diagnosis by US [10, 26, 27], and our study
confirmed these doubts. However, our data also
highlighted a very interesting fact: LR- and LR+ analyses
gave values of 0.1 and 1.9, respectively. In general, values
of LR−≤0:1 in a diagnostic test indicate a great reliability
Table 1: Clinical and demographic characteristics of the enrolled
patients.
n = 57
Age (y) 42 ± 12:0
M/F 16/41




AST (U/L) 18.5 (16-27)
Elevated AST (>40U/L) 3 (5.26%)
ALT (U/L) 29 (20-39)
Elevated ALT (>40U/L) 9 (15.8%)
Total cholesterol (mg/dL) 192 ± 28:7
Triglycerides (mg/dL) 113 (68-140)
HDL (mg/dL) 54 ± 14:0
LDL (mg/dL) 115:0 ± 27:2
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in excluding the disease, whereas values of LR+>10 indi-
cate that the test is able to indicate its presence with a
high level of confidence. Based on these observations,
our finding of LR−≤0:1 indicates that US has a high reli-
ability in defining the absence of steatosis in obese subjects
but that, with a LR+ of 1.9, it is not very reliable for deter-
mining its presence [28, 29].
The limited reliability of US in detecting steatosis in
patients with morbid obesity, shown by the low specificity
and low LR+, probably depends on a number of factors,
mainly related to the physics of US diffusion. It is a
known fact that the deeper US waves go, the greater their
diffraction and the lower their resolution capacity. In
short, the ability of US to define a correct echo pattern
is reduced, and very often an incorrect increase in the reg-
ulation curve of the gain increases the echogenicity of the
liver, producing false positives; the bright liver typical of
steatosis is, in fact, hyperechoic.
Studies conducted on obese subjects have reported a 6-
94% frequency of fibrosis and a 26-55% frequency of NASH
[30–34]. In our series, according to the SAF score [23],
NASH was present in 61.4% of patients. Our results are
slightly higher than the average in the literature, likely due
to various phenomena occurring in patients with morbid
obesity, above all insulin resistance because of the greater
degree and extent of inflammation. Since there is no reliable
serum parameter for NASH, noninvasive parameters to
define the presence of steatohepatitis [1] were not evaluated
in our series.
The prevalence of fibrosis in all subjects with steatosis
was 87%. In the 11 subjects with NAFL alone without inflam-
mation, a fibrosis score of F1 was found. In NASH patients,
the prevalence of fibrosis was 94% (95% CI: 0.89-0.98), dis-
tributed as follows: F1 in 12 cases (34.1%; 95% CI: 21-50%),
F2 in 18 patients (51%; 95% CI: 18-35%), F3 (bridging fibro-
sis) in 2 patients (5.7%; 95% CI: 1-30%), and F4 (cirrhosis) in
1 case (2.8%; 95% CI: 0.5-20).
These data suggest several considerations. First, it is
possible to find small amounts of fibrosis even in patients
with NAFL alone, as reported in the literature. This may
depend on many factors: the limits of biopsy sampling,
or the possibility of finding a disease in phases where

















































Figure 1: (a) Steatosis grading according to Kleiner. (b) Diagnosis of NAFLD according to SAF score. (c) Fibrosis score according to Kleiner.
Table 2: Diagnostic reliability of ultrasound in the diagnosis of
steatosis in the study population.
Ultrasound
Sensitivity 95% (95% CI: 84-99)
Specificity 50% (95% CI: 18-81)
Likelihood ratio + 1.91% (95% CI: 1.1-3.5)
Likelihood ratio - 0.1% (95% CI: 0.02-0.4)
Positive predictive value 89.4% (95% CI: 82-94)
Negative predictive value 71% (95% CI: 36-92)
Accuracy 87% (95% CI: 75-94)
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Second, despite the prevalence of fibrosis falling within the
range reported by the literature, our percentage of
advanced fibrosis (≥F3) was very low.
Although the validity of our considerations is limited
by the small study population, this observation may also
be due to the relatively young age of our patients (41
years). Age is indeed known to be one of the most impor-
tant variables influencing NASH onset and evolution; in
fact, as age increases, there is also an increased incidence
of insulin resistance, MS, and diabetes mellitus [35, 36].
In a systematic review of this issue, Argo et al. found that
age was the independent predictor of advanced fibrosis
(HR 0.98, 95% CI: 0.96-0.99, p = 0:009) and that young
people have a lower risk for the presence of fibrosis [37].
However, this study did not show any relationship
between fibrosis and diabetes, in contrast to McPherson
et al. who found an important role for diabetes among
patients with NAFL: in fact, 80% of those having fibrosis
progression were diabetic at the follow-up liver biopsy
compared to 25% of nonprogressors (p = 0:005) [38].
Moreover, there is another reason which may explain the
lower frequency of fibrosis in our study: the high prevalence
of premenopausal women. Gender and reproductive states
may influence the degree of fibrosis in patients with NASH.
Longitudinal studies suggest that the incidence of NAFLD
is higher in males than in females, and the incidence is higher
in menopausal (7.5%)/postmenopausal (6.1%) women as
compared to premenopausal (3.5%) women [39]. In addi-
tion, an Italian multicenter study found that men with
NAFLD were approximately 10 years younger than women,
confirming previous findings that premenopausal women
are somehow “protected” from NAFLD [40].
Yang et al. found an adjusted cumulative odds ratio
(ACOR) and 95% confidence interval (CI) for greater fibrosis
severity of 1.4 (0.9, 2.1) (p = 0:17) for postmenopausal
women, with premenopausal women as a reference [41].
Finally, Wang Z. et al., studying the predictive factors of
NASH and fibrosis in women with different BMI and age,
reported that the prevalence of NASH seems to be consider-
ably higher in obese and postmenopausal women with
NAFLD [42].
Further, the use of serum markers to evaluate the pres-
ence of fibrosis did not yield reliable results. The AUROC
values of the BARD and NAFLD scores showed low accuracy.
Only the FIB-4 index presented an acceptable ROC curve of
0.7, but the modest results obtained in our study were not
enough to indicate it as being reliable. Our results are in dis-
agreement with the literature, which recognizes an important
role for the FIB-4 index and NAFLD score, but it is possible
that the young age of our population played an important
role in this result, given that the individual’s age is included
in the calculation of the scores. However, even in this case,
some considerations must be made: (1) our limited number
of cases may have reduced the reliability of the results, as
shown by the wide confidence interval; (2) most of the
patients reported in the guidelines did not suffer from mor-
bid obesity [1]; (3) our patients showed a low degree of fibro-
sis; in fact, the accuracy of noninvasive fibrosis tests is known
to be very limited for F ≤ 2 values [1]; (4) it possible that the
young age of our patients also conditioned the results of the
noninvasive fibrosis tests because most of the tools/calcula-
tors assessed take the age of the individual into account.
Table 3: Reliability of serum markers in the definition of moderate fibrosis (F ≥ 2).
NAFLD score BARD score FIB-4
Cut − off<−1:455
% (95% CI)
Cut − off ≥ 2
% (95% CI)
Cut − off > 0:41
% (95% CI)
Sensitivity 30 (12-54) 46 (27-67) 68 (46-85)
Specificity 89 (52-99) 54 (27-79) 67 (52-98)
Likelihood ratio + 2.7 (1.3-5.5) 0.6 (0.1-3) 2 (1.3-3.2)
Likelihood ratio - 0.8 (0.1-5.1) 1.1 (0.84-1.34) 0.5 (0.1-4.4)
Positive predictive value 93 (82-97) 50 (13-86) 77 (45-92)
Negative predictive value 22 (12-38) 36 (31-42) 55 (29-78)
Accuracy 64.3 (48-78.5) 37 (23-54) 60 (42-74)
AUROC∗ 0.53 0.5 0.7












0 20 40 60 80 100
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Figure 2: FIB-4 ROC curve with area under the curve of 0.7 and the
best cut-off point.
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Finally, we have to underline that our patients were all Ital-
ian, and therefore, our results cannot be generalized; in fact,
both NASH and its evolution may vary according to ethnic-
ity. For example, Hispanics with obesity and diabetes have
a far higher risk for advanced liver disease than other racial
or ethnic groups, indicating the potential involvement of
other factors such as genetic variants [43].
5. Conclusions
In conclusion, our data show that US is a method that can
exclude the presence of steatosis in subjects with severe obe-
sity with a good degree of reliability.
Steatosis assessment with the controlled attenuation
parameter using XL probes has recently been proposed in
obese subjects and seems to have a good level of accuracy.
It is advisable, in our opinion, to reserve this examination
for patients in whom US images suggest steatosis, in order
to confirm and eventually stage it.
The literature data report that, even in subjects with obe-
sity, fibrosis serum markers are reliable; however, in our
study, the accuracy of fibrosis evaluation with serummarkers
appeared to be limited, though this may be due to the low
prevalence of fibrosis in our patients. In any case, the nonin-
vasive evaluation of fibrosis in patients with morbid obesity is
a chapter still to be written, as even elastosonographic
methods have their limits. Although special XL probes,
which seem to be able to reduce the need for nondiagnostic
tests in subjects with severe obesity, have recently been used
for morbidly obese patients, the values obtained are lower
than those in nonobese subjects, and therefore, there are no
well-defined cut-offs that can indicate the reliability of the
method [15].
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